Ovarian cancer chemotherapy: Carboplatin as standard

Lancet

Volumn 360, Issue 9332, 2002, Pages 500-501

  Tattersall, Martin H N ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; TAXANE DERIVATIVE;

CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; META ANALYSIS; NOTE; OVARY CARCINOMA; PRIORITY JOURNAL; QUALITY OF LIFE; STANDARD; TREATMENT OUTCOME;

EID: 0037125591     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09757-X     Document Type: Note

References (14)

1. Clark T.G., Stewart M.E., Altman D.G., et al. A prognostic model for ovarian cancer. Br J Cancer. 85:2001;944-952.
2. Junor E.J., Hole D.J., McNulty L., et al. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol. 106:1999;1130-1136.
3. Advanced Ovarian Cancer Trialists' Group . Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ. 303:1991;884-893.
4. Advanced Ovarian Cancer Trialists' Group . Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer. 78:1998;1479-1487.
5. The Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian cancer: a meta-analysis. J Clin Oncol. 9:1991;1668-1674.
6. A'Hern R.P., Gore M.E. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol. 13:1995;726-732.
7. McGuire W.P., Rowinsky E.K., Rosenheim N.B., et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 111:1989;273-279.
8. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage 3 and 4 ovarian cancer. N Engl J Med. 334:1996;1-6.
9. Muggia F.M., Braly P.S., Brady M.F., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 18:2000;106-115.
10. Piccart M.J., Bertelsen K., James K., et al. Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: 3 year results. J Natl Cancer Inst. 92:2000;699-708.
11. The ICON collaborators . ICON 2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophos phamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet. 352:1998;1571-1576.
12. Elit L.M., Levine M.N., Gafni A., et al. Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing and application of a bedside decision instrument. Gynecol Oncol. 62:1996;329-335.
13. Im D.D., McGuire W.P., Rosenheim N.B. Contemporary management of ovarian cancer. Obstet Gynecol Clin N Am. 28:2001;759-773.
14. Christian J., Thomas H. Ovarian cancer chemotherapy. Cancer Treat Rev. 27:2001;99-109.